## Effects of methylated catechins on 3-methylcholanthrene-mediated induction of CYP1A1 enzyme

Masakuni Degawa<sup>1,2</sup>, Masashi Sekimoto<sup>2</sup>,
Toshiyuki Wakimoto<sup>3</sup>, Toshiyuki Kan<sup>1,3</sup> and Kiyomitsu Nemoto<sup>2</sup>

<sup>1</sup>Global COE Program, <sup>2</sup>Department of Molecular Toxicology,

<sup>3</sup>Department of Synthetic Organic & Medicinal Chemistry,
Graduate School of Pharmaceutical Sciences, University of Shizuoka

In the present study, we examined the effects of 3"- or 4"-*O*-methylated catechins, such as 3"-Me-CG, 4"-Me-CG, 3"-Me-ECG, 4"-Me-ECG, 3"-Me-GCG, 4"-Me-GCG, 3"-Me-EGCG and 4"-Me-EGCG, on the 3-methylcholanthrene (MC)-mediated induction of CYP1A1 enzyme at levels of mRNA, protein, and activity (ethoxyresorufin *O*-deethylation activity) in HepG2-A10 cells. The *O*-methylated CG and ECG derivatives, but not the *O*-methylated GCG and EGCG derivatives, augmented the MC-mediated induction of CYP1A1 at levels of mRNA and protein. On the other hand, *O*-methylated ECG derivatives, but not other compounds including *O*-methylated CG, showed capacities for enhancing MC-mediated induction of CYP1A1 at the level of enzyme activity. The present findings demonstrate that the *O*-methylated GC and ECG derivatives show capacities for enhancing MC-mediated induction of CYP1A1 and further suggest that the *O*-methylated GCs, but not the *O*-methylated ECGs, show capacities for inhibiting the enzyme activity of CYP1A1.